Outcome | Comparison | Number of trials (n) | RRR (95% CI) |
---|---|---|---|
*ICSs = inhaled corticosteroids; SABAs = short acting β2 agonists; LABAs = long acting β2 agonists; LPMs/RAs = leukotriene pathway modifiers/receptor antagonists. Other abbreviations defined in glossary; RRR and CI calculated from data in article. | |||
†Calculated using a random effects model. | |||
Rate of exacerbations | ICSs v placebo or SABAs | 11 (9418) | 54% (38 to 66)† |
LABAs v placebo | 9 (2854) | 25% (12 to 36) | |
ICSs plus LABAs v ICSs | 7 (3886) | 26% (9 to 39) | |
ICSs plus LABAs v doubled dosage of ICSs | 10 (5680) | 14% (4 to 24) | |
LPMs/RAs v placebo | 7 (4375) | 41% (29 to 51) | |
ICSs plus anti-IgE antibodies v ICSs | 3 (1388) | 45% (34 to 55) |